Daewoong Group Indonesia

Daewoong Group Indonesia is the Indonesian division of the South Korean pharmaceutical leader Daewoong Pharmaceutical, operating through several key entities including PT Daewoong Infion and PT Daewoong Biologics Indonesia. The company is a pioneer in the Indonesian biotech sector, having established the country's first biologics manufacturing plant to produce erythropoietin and other recombinant proteins. Their product portfolio spans aesthetics with Nabota, gastroenterology with Fexuprazan, and advanced wound care with Easyef. Daewoong is heavily invested in local R&D, particularly in stem cell therapy and regenerative medicine, through collaborations with leading Indonesian universities. The group plays a strategic role in enhancing Indonesia's pharmaceutical self-sufficiency through localized production and technology transfer.